Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston R&D hub last year, has attracted high-profile investors for its Series B round. The actress Uma Thurman added to the biotech’s coffers, Bloomberg reported Tuesday, helping bring the financing round to $30 million.
The round was co-led by Apeiron Investment Group and Catalio Capital Management. Sensei also brought on new investors Pura Vida Investments and several international family offices, as well as existing…
